Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C

被引：14
作者：
Barnett, SW [1 ]
Srivastava, IK [1 ]
Ulmer, JB [1 ]
Donnelly, JJ [1 ]
Rappuoli, R [1 ]
机构：
[1] Chiron Corp, Vaccines Res Dept, Emeryville, CA 94608 USA
来源：
MICROBES AND INFECTION | 2005年 / 7卷 / 14期
关键词：
HIV; envelope; neutralizing antibodies; vaccine;
D O I：
10.1016/j.micinf.2005.07.018
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The urgent need for a vaccine against HIV/AIDS requires that multiple strategies be employed and evaluated in a clinical setting. V2-loop deleted trimeric envelope (Env) immunogens (protein and DNA) from subtypes B and C human immunodeficiency virus type 1 (HIV-1) strains were produced for ongoing and future clinical evaluations with other HIV antigens, adjuvants and deliveries. (c) 2005 Elsevier SAS. All rights reserved.
引用
收藏
页码：1386 / 1391
页数：6
相关论文
共 30 条
  • [1] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    Amara, RR
    Villinger, F
    Altman, JD
    Lydy, SL
    O'Neil, SP
    Staprans, SI
    Montefiori, DC
    Xu, Y
    Herndon, JG
    Wyatt, LS
    Candido, MA
    Kozyr, NL
    Earl, PL
    Smith, JM
    Ma, HL
    Grimm, BD
    Hulsey, ML
    Miller, J
    McClure, HM
    McNicholl, JM
    Moss, B
    Robinson, HL
    [J]. SCIENCE, 2001, 292 (5514) : 69 - 74
  • [2] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
    Baba, TW
    Liska, V
    Hofmann-Lehmann, R
    Vlasak, J
    Xu, WD
    Ayehunie, S
    Cavacini, LA
    Posner, MR
    Katinger, H
    Stiegler, G
    Bernacky, BJ
    Rizvi, TA
    Schmidt, R
    Hill, LR
    Keeling, ME
    Lu, YC
    Wright, JE
    Chou, TC
    Ruprecht, RM
    [J]. NATURE MEDICINE, 2000, 6 (02) : 200 - 206
  • [3] The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
    Barnet, SW
    Lu, S
    Srivastava, I
    Cherpelis, S
    Gettie, A
    Blanchard, J
    Wang, S
    Mboudjeka, I
    Leung, L
    Lian, Y
    Fong, A
    Buckner, C
    Ly, A
    Hilt, S
    Ulmer, J
    Wild, CT
    Mascola, JR
    Stamatatos, L
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (12) : 5526 - 5540
  • [4] Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys
    Barouch, DH
    Kunstman, J
    Glowczwskie, J
    Kunstman, KJ
    Egan, MA
    Peyerl, FW
    Santra, S
    Kuroda, MJ
    Schmitz, JE
    Beaudry, K
    Krivulka, GR
    Lifton, MA
    Gorgone, DA
    Wolinsky, SM
    Letvin, NL
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (13) : 7367 - 7375
  • [5] Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
    Barouch, DH
    Kunstman, J
    Kuroda, MJ
    Schmitz, JE
    Santra, S
    Peyerl, FW
    Krivulka, GR
    Beaudry, K
    Lifton, MA
    Gorgone, DA
    Montefiori, DC
    Lewis, MG
    Wolinsky, SM
    Letvin, NL
    [J]. NATURE, 2002, 415 (6869) : 335 - 339
  • [6] DNA vaccination for HIV-1 and SIV
    Barouch, DH
    Letvin, NL
    [J]. INTERVIROLOGY, 2000, 43 (4-6) : 282 - 287
  • [7] Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors
    Betts, MR
    Krowka, JF
    Kepler, TB
    Davidian, M
    Christopherson, C
    Kwok, S
    Louie, L
    Eron, J
    Sheppard, H
    Frelinger, JA
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (13) : 1219 - 1228
  • [8] VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    BORROW, P
    LEWICKI, H
    HAHN, BH
    SHAW, GM
    OLDSTONE, MBA
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (09) : 6103 - 6110
  • [9] Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV
    Buckner, C
    Gines, LG
    Saunders, CJ
    Vojtech, L
    Srivastava, I
    Gettie, A
    Bohm, R
    Blanchard, J
    Barnett, SW
    Safrit, JT
    Stamatatos, L
    [J]. VIROLOGY, 2004, 320 (01) : 167 - 180
  • [10] DNA vaccination with the human immunodeficiency virus type 1 SF162ΔV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques
    Cherpelis, S
    Shrivastava, I
    Gettie, A
    Jin, X
    Ho, DD
    Barnett, SW
    Stamatatos, L
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (03) : 1547 - 1550
123